Under the agreement, the companies will conduct a feasibility study to develop a dry powder inhaler (DPI) dosage form for a RespiVert compound.
SkyePharma chief executive officer Peter Grant said: "We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases."
RespiVert compounds are used for the treatment of patients with severe, chronic respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma.
SkyePharma is a drug delivery company developing oral and inhalation products.